Loading...
Market
What phase will the first human trial of the implantable device for fentanyl overdoses reach by 2025?
2
Resolution / Starting Odds
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
No trial • 25%
Clinical trial registries and publications
Story
New Implantable Device to Combat Fentanyl Overdoses in High-Risk Individuals Tested in Animals
Oct 24, 2024, 11:06 AM
Researchers have developed a promising implantable device aimed at counteracting the effects of fentanyl overdoses. Currently tested in animals, the device is designed to be inserted under the skin, similar to a pacemaker, and has the potential to significantly reduce opioid-related deaths, particularly among high-risk individuals. The device works by detecting an opioid overdose and delivering treatment automatically, addressing a critical gap in the current overdose response system, which relies heavily on the immediate availability of naloxone. Naloxone has proven effective in saving lives, but its success is contingent upon someone being present to administer it quickly, a scenario that is not always possible. Continued development of this device could pave the way for its use in humans in the future.
View original story
Similar markets
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Q3 2025 (Jul-Sep) • 25%
Q4 2025 (Oct-Dec) • 25%
Not by end of 2025 • 25%
Not at all • 25%
Yes • 50%
No • 50%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Q1 2025 (Jan-Mar) • 25%
Q2 2025 (Apr-Jun) • 25%
Not by mid-2025 • 25%
Not at all • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant improvement • 25%
Worsening of symptoms • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%